A Phase III Open-Label Titration Trial to Evaluate the Effectiveness and Safety of Different Doses of a Dermal Application of Testosterone MD-Lotion (Cutaneous Solution) in Hypogonadal Men to Evaluate Skin-safety.

Trial Profile

A Phase III Open-Label Titration Trial to Evaluate the Effectiveness and Safety of Different Doses of a Dermal Application of Testosterone MD-Lotion (Cutaneous Solution) in Hypogonadal Men to Evaluate Skin-safety.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2016

At a glance

  • Drugs Testosterone (Primary)
  • Indications Hypogonadism
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors Acrux
  • Most Recent Events

    • 29 Jun 2011 Results published on the Clinical Endocrinology website.
    • 04 Jan 2011 Eli Lilly added as company and lead trial centre as reported by ClinicalTrials.gov. (Extension trial: NCT00857454)
    • 04 Jan 2011 Eli Lilly added as company and lead trial centre as reported by ClinicalTrials.gov. (Extension trial: NCT00857454)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top